- Published on
Ophthalmology – Down Syndrome (Trisomy 21)
Down syndrome, also known as Trisomy 21, is a chromosomal disorder caused by the presence of an extra copy of chromosome 21. It was first described by John Langdon Down in 1866. The condition affects individuals worldwide across all ethnic and socioeconomic groups and is one of the most common genetic causes of intellectual disability.
The incidence is approximately 1 in 733 live births in the United States, with risk strongly associated with advanced maternal age. For example, the risk increases significantly from about 1 in 1,562 in women aged 20–24 to about 1 in 19 in women over 45. Increased paternal age has also been identified as a contributing risk factor. Most cases result from meiotic nondisjunction, leading to a full extra chromosome, although partial or mosaic forms may also occur.
Clinically, Down syndrome presents with a characteristic set of physical features. These include a round face, small chin (microgenia), macroglossia (large tongue), and short neck. Ocular findings are particularly relevant in ophthalmology and include epicanthal folds, upward slanting palpebral fissures, and Brushfield spots—small whitish or grayish speckles seen at the periphery of the iris. Patients often also have strabismus, cataracts, and other visual abnormalities. General features include hypotonia, short stature, single palmar crease, and varying degrees of intellectual disability and speech delay.
Down syndrome is associated with multiple systemic conditions. These include thyroid disorders, gastrointestinal anomalies, hematologic malignancies, and an increased risk of early-onset Alzheimer’s disease, often developing before age 50. Fertility is typically reduced, especially in males.
Diagnosis can be made prenatally through screening and diagnostic techniques such as amniocentesis, chorionic villus sampling, or umbilical cord blood sampling. Postnatally, diagnosis is confirmed by karyotype analysis. Ophthalmic evaluation may include imaging such as optical coherence tomography (OCT), which can demonstrate macular hypoplasia, and visual electrophysiologic testing.
There is no cure for Down syndrome, so management focuses on supportive care and treatment of associated conditions. Early intervention programs, including speech therapy, occupational therapy, and educational support, significantly improve developmental outcomes. Ophthalmic issues such as strabismus or cataracts should be managed appropriately to optimize visual function.
Follow-up care is lifelong and multidisciplinary. With advances in medical care and supportive services, life expectancy has improved significantly, increasing from approximately 25 years in 1980 to nearly 50 years or more today. Many individuals now live into adulthood with improved quality of life, although neurodegenerative complications remain a concern later in life.
Down syndrome, also known as Trisomy 21, is a chromosomal disorder caused by the presence of an extra copy of chromosome 21. It was first described by John Langdon Down in 1866. The condition affects individuals worldwide across all ethnic and socioeconomic groups and is one of the most common genetic causes of intellectual disability.
The incidence is approximately 1 in 733 live births in the United States, with risk strongly associated with advanced maternal age. For example, the risk increases significantly from about 1 in 1,562 in women aged 20–24 to about 1 in 19 in women over 45. Increased paternal age has also been identified as a contributing risk factor. Most cases result from meiotic nondisjunction, leading to a full extra chromosome, although partial or mosaic forms may also occur.
Clinically, Down syndrome presents with a characteristic set of physical features. These include a round face, small chin (microgenia), macroglossia (large tongue), and short neck. Ocular findings are particularly relevant in ophthalmology and include epicanthal folds, upward slanting palpebral fissures, and Brushfield spots—small whitish or grayish speckles seen at the periphery of the iris. Patients often also have strabismus, cataracts, and other visual abnormalities. General features include hypotonia, short stature, single palmar crease, and varying degrees of intellectual disability and speech delay.
Down syndrome is associated with multiple systemic conditions. These include thyroid disorders, gastrointestinal anomalies, hematologic malignancies, and an increased risk of early-onset Alzheimer’s disease, often developing before age 50. Fertility is typically reduced, especially in males.
Diagnosis can be made prenatally through screening and diagnostic techniques such as amniocentesis, chorionic villus sampling, or umbilical cord blood sampling. Postnatally, diagnosis is confirmed by karyotype analysis. Ophthalmic evaluation may include imaging such as optical coherence tomography (OCT), which can demonstrate macular hypoplasia, and visual electrophysiologic testing.
There is no cure for Down syndrome, so management focuses on supportive care and treatment of associated conditions. Early intervention programs, including speech therapy, occupational therapy, and educational support, significantly improve developmental outcomes. Ophthalmic issues such as strabismus or cataracts should be managed appropriately to optimize visual function.
Follow-up care is lifelong and multidisciplinary. With advances in medical care and supportive services, life expectancy has improved significantly, increasing from approximately 25 years in 1980 to nearly 50 years or more today. Many individuals now live into adulthood with improved quality of life, although neurodegenerative complications remain a concern later in life.
0 Comments
